Evommune’s novel human tissue-based assay system is proving to be a key differentiator as the company develops therapies to control chronic inflammation in autoimmune diseases.
https://www.pharmalive.com/wp-content/uploads/2022/10/Evommune.jpg350625BioSpacehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngBioSpace2022-10-11 10:03:012022-10-11 10:03:01Evommune’s human tissue-based approach enables discovery and development of safer, innovative chronic inflammation therapies
